9th India Pharma Highlights Policy Push and Innovation Driving Sectoral Growth

The 9th edition of India Pharma 2026, the flagship event of the Department of Pharmaceuticals (DoP), Ministry of Chemicals & Fertilizers, Government of India, commenced today in New Delhi. Organized in collaboration with the Federation of Indian Chambers of Commerce and Industry (FICCI) and the Indian Pharmaceutical Alliance (IPA), the two-day conference (April 13–14) brings together key stakeholders from across the global pharmaceutical and healthcare ecosystem, with a strong focus on innovation, self-reliance, and global leadership.

Addressing the inaugural session virtually Union Minister of Health & Family Welfare and Chemicals & Fertilizers, J.P. Nadda, emphasized that the platform reflects both the strength and growing global relevance of India’s pharmaceutical sector.He added that India Pharma 2026 provides a vital platform to foster dialogue, partnerships, and a forward-looking roadmap for the sector.
Minister of State for Health & Family Welfare and Chemicals & Fertilizers, Smt. Anupriya Patel, highlighted that India is undergoing a significant transition from being a global generics leader to an emerging biopharma innovation hub.
Manoj Joshi, Secretary, Department of Pharmaceuticals, stressed the need to accelerate innovation timelines, strengthen startup ecosystems, and build robust infrastructure for clinical trials and advanced research. He highlighted the importance of enhanced funding mechanisms, closer industry-government collaboration, and development of skilled talent.
Smt. Punya Salila Srivastava, Secretary, Ministry of Health & Family Welfare, reiterated the Government’s commitment to strengthening the regulatory ecosystem and enabling innovation.
Arjun Juneja, Chair, FICCI Pharma Committee and COO, Mankind Pharma, highlighted India’s strong pharmaceutical base, noting the presence of over 3,000 companies and more than 10,500 manufacturing facilities, including the highest number of USFDA-compliant plants outside the United States.
Achin Gupta, Co-Chair, FICCI Pharma Committee and MD & Global CEO, Cipla Ltd, delivered the vote of thanks.(updated on 13th April 2026)